Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics (ATOS), with a price target of $9. The company’s shares opened today at $4.47.
“Atossa Genetics announced IRB (Institutional Review Board) approval for use of oral endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. This follows clearance from the FDA announced on 3/14.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.9% and a 34.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Based on Atossa Genetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.31 million. In comparison, last year the company had a GAAP net loss of $1.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.